ANIX

Anixa Biosciences, Inc. (ANIX) | Rumor.io

Anixa Biosciences

ANIX

Attention (50-day avg)0%

Attention rank (50-day avg)#3,146

Bullish sentiment (50-day avg)71%

Price to earnings ratio-8.24

Market capitalization97M

Earnings per share-0.32

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-11M

Social

What share of all stock conversation is about ANIX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% +0

Jun 26

Anixa Biosciences' breast cancer vaccine achieved all major primary endpoints in Phase 1, with 74% of participants generating protocol-defined immune responses.
The company also reported positive survival observations from its ongoing CAR-T phase 1 trial in ovarian cancer.
The stock did not move significantly despite the positive clinical updates, with one post speculating that the market is "fucked" and another questioning why the stock is dropping.

Generated by AI

Sentiment

Of the messages about ANIX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	50%	55.56% -27.78	75.13% -14.11
Bearish	0%	50%	44.44% +27.78	24.87% +14.11

Bullish· Dec 11

The breast cancer vaccine developed by Anixa Biosciences has shown promising Phase 1 results, meeting all major primary endpoints and eliciting protocol-defined immune responses in 74% of participants.
The company's strong pipeline includes a breast cancer vaccine and a novel CAR-T therapy for ovarian cancer, with Phase 2 trials for the vaccine currently in preparation.
Anixa Biosciences has secured international patent extensions and a strong IP position, with patent developments worldwide, including in China, improving the global protection for the company's technology.

Bearish· Mar 24

The stock price of Anixa Biosciences has dropped significantly after a company called H.C. Wainwright & Co. got involved.
The company's recent stock offering has led to a massive dilution of shares, causing the stock price to plummet.
The market believes that the stock is overvalued, and the company's attempts to pump up the price have been unsuccessful, leading to a significant decline in value.

Generated by AI

Topics

Of the messages about ANIX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	87.5%	85%	86.06%
Technical Analysis	—	0%	10%	11.52%
Analysts	—	12.5%	5%	0.91%
Controversies	—	0%	0%	0.61%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0.91%

Announcements· Apr 17

Anixa Biosciences and Cleveland Clinic presented positive data for Phase 1 study of breast cancer vaccine, with 100% biomarker readout and potential for accelerated path to knowledge of effectiveness.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated that the company is heartened by the data and looks forward to additional studies.
Anixa Biosciences clarified a poster presentation on their website, providing additional information on their breast cancer vaccine study.

Technical Analysis· Apr 24

$ANIX has a strong support level at $3, with potential for a breakout to $3.45 and $3.70.
A break above $3.40 could send the stock toward $5.00, with key technical analysis levels to watch including $3.16, $3.22, $3.34, $3.48, $3.74, and $4.00.
The stock is consolidating between $3.15 and $3.25, with a potential move higher if it can reclaim this area, and a possible PR catalyst could send the stock flying.

Generated by AI

Community

Of the messages about ANIX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	81.82%	37.5%	33.02%
Newcomers	0%	18.18%	62.5%	66.98%

Regulars· Apr 17

Anixa Biosciences and Cleveland Clinic have presented positive data for the Phase 1 study of their breast cancer vaccine, which is a significant development for the company.
The stock had a couple of point runup into the announcement and sold off afterwards, but one participant has a core position and has added to it.
The company has clarified its poster presentation on its website, and the data from the Phase 1 study is being presented at the American Association for Cancer Research (#AACR).

Newcomers· Aug 25

Newcomers are discussing the volatility of ANIX, with some users flipping stocks in the gap and looking for specific price targets.
Some users are sharing their experience with short trades on ANIX, with one user describing it as a "classic VWAP short trade" with a small profit.
The recent news about Anixa Biosciences' Covid-19 compounds being effective against the Delta variant is being highlighted as a strong catalyst for the stock's price, with some users anticipating a significant increase in price.

Generated by AI

News

Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

8d agoMorningstar

Anixa Biosciences adds UPenn oncologist to advisory board

13d agoInvesting.com

Also Discussed

Investors talking about ANIX also mention

#	Name	Attention
1	Myomo Inc.MYO	0%0
2	My Size, Inc.MYSZ	0%new
3	Usio Inc.USIO	0%0
4	INmune Bio Inc.INMB	0%0
5	Ideal Power Inc.IPWR	0%0
6	MOND - Mondee Holdings, Inc.	——
7	CareCloud Inc.CCLD	0%new
8	Lightbridge CorporationLTBR	0%+0
9	Peraso Inc.PRSO	0%0
10	Cardiff Oncology Inc.CRDF	0%+0

Anixa Biosciences, Inc.

Healthcare
Biotechnology

Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The company develops cancer vaccines and cell-based immunotherapies, including programs centered on breast cancer, ovarian cancer, and other hard-to-treat solid tumors. Its work includes vaccine platforms designed to stimulate immune responses against cancer-related targets and a CAR-T-based therapeutic approach aimed at oncology applications. Anixa Biosciences also explores complementary diagnostics and related research programs that support early detection and cancer management. Headquartered in San Jose, California, Anixa Biosciences serves the biotechnology and oncology markets through a pipeline of current products and development programs that address unmet needs in cancer care.

Website

Location

3150 Almaden Expressway

San Jose, CA, 95118

United States

Social

What share of all stock conversation is about ANIX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% +0

Jun 26

Anixa Biosciences' breast cancer vaccine achieved all major primary endpoints in Phase 1, with 74% of participants generating protocol-defined immune responses.
The company also reported positive survival observations from its ongoing CAR-T phase 1 trial in ovarian cancer.
The stock did not move significantly despite the positive clinical updates, with one post speculating that the market is "fucked" and another questioning why the stock is dropping.

Generated by AI

Sentiment

Of the messages about ANIX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	50%	55.56% -27.78	75.13% -14.11
Bearish	0%	50%	44.44% +27.78	24.87% +14.11

Bullish· Dec 11

The breast cancer vaccine developed by Anixa Biosciences has shown promising Phase 1 results, meeting all major primary endpoints and eliciting protocol-defined immune responses in 74% of participants.
The company's strong pipeline includes a breast cancer vaccine and a novel CAR-T therapy for ovarian cancer, with Phase 2 trials for the vaccine currently in preparation.
Anixa Biosciences has secured international patent extensions and a strong IP position, with patent developments worldwide, including in China, improving the global protection for the company's technology.

Bearish· Mar 24

The stock price of Anixa Biosciences has dropped significantly after a company called H.C. Wainwright & Co. got involved.
The company's recent stock offering has led to a massive dilution of shares, causing the stock price to plummet.
The market believes that the stock is overvalued, and the company's attempts to pump up the price have been unsuccessful, leading to a significant decline in value.

Generated by AI

Topics

Of the messages about ANIX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	87.5%	85%	86.06%
Technical Analysis	—	0%	10%	11.52%
Analysts	—	12.5%	5%	0.91%
Controversies	—	0%	0%	0.61%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0.91%

Announcements· Apr 17

Anixa Biosciences and Cleveland Clinic presented positive data for Phase 1 study of breast cancer vaccine, with 100% biomarker readout and potential for accelerated path to knowledge of effectiveness.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated that the company is heartened by the data and looks forward to additional studies.
Anixa Biosciences clarified a poster presentation on their website, providing additional information on their breast cancer vaccine study.

Technical Analysis· Apr 24

$ANIX has a strong support level at $3, with potential for a breakout to $3.45 and $3.70.
A break above $3.40 could send the stock toward $5.00, with key technical analysis levels to watch including $3.16, $3.22, $3.34, $3.48, $3.74, and $4.00.
The stock is consolidating between $3.15 and $3.25, with a potential move higher if it can reclaim this area, and a possible PR catalyst could send the stock flying.

Generated by AI

Community

Of the messages about ANIX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	81.82%	37.5%	33.02%
Newcomers	0%	18.18%	62.5%	66.98%

Regulars· Apr 17

Anixa Biosciences and Cleveland Clinic have presented positive data for the Phase 1 study of their breast cancer vaccine, which is a significant development for the company.
The stock had a couple of point runup into the announcement and sold off afterwards, but one participant has a core position and has added to it.
The company has clarified its poster presentation on its website, and the data from the Phase 1 study is being presented at the American Association for Cancer Research (#AACR).

Newcomers· Aug 25

Newcomers are discussing the volatility of ANIX, with some users flipping stocks in the gap and looking for specific price targets.
Some users are sharing their experience with short trades on ANIX, with one user describing it as a "classic VWAP short trade" with a small profit.
The recent news about Anixa Biosciences' Covid-19 compounds being effective against the Delta variant is being highlighted as a strong catalyst for the stock's price, with some users anticipating a significant increase in price.

Generated by AI

Anixa Biosciences

Social

Jun 26

Bullish· Dec 11

Bearish· Mar 24

Announcements· Apr 17

Technical Analysis· Apr 24

Regulars· Apr 17

Newcomers· Aug 25

Anixa Biosciences CEO Amit Kumar buys $19,460 in common stock

Anixa Biosciences director buys $13,799 in ANIX stock

Anixa Biosciences director Lewis Titterton Jr. buys $131,906 in stock

H.C. Wainwright lowers Anixa Biosciences stock price target to $6

Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

Anixa Biosciences adds UPenn oncologist to advisory board

Also Discussed

Anixa Biosciences, Inc.

Company Information

Location

Anixa Biosciences CEO Amit Kumar buys $19,460 in common stock

Anixa Biosciences director buys $13,799 in ANIX stock

Anixa Biosciences director Lewis Titterton Jr. buys $131,906 in stock

H.C. Wainwright lowers Anixa Biosciences stock price target to $6

Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

Anixa Biosciences adds UPenn oncologist to advisory board

Also Discussed

Social

Jun 26

Bullish· Dec 11

Bearish· Mar 24

Announcements· Apr 17

Technical Analysis· Apr 24

Regulars· Apr 17

Newcomers· Aug 25